The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
Status:
Not yet recruiting
Trial end date:
2025-06-14
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the long term safety and efficacy of orally
administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE),
discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have
completed the 24 week treatment period of Willow study (MS200569_0003 [NCT05162586]).
Phase:
Phase 2
Details
Lead Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany